Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:alternativeName |
IRAK4 degrader
|
| gptkbp:clinicalTrialPhase |
Phase 1
|
| gptkbp:companyPipeline |
Kymera Therapeutics pipeline
|
| gptkbp:developedBy |
gptkb:Kymera_Therapeutics
|
| https://www.w3.org/2000/01/rdf-schema#label |
KT-474
|
| gptkbp:indication |
autoimmune diseases
inflammatory diseases |
| gptkbp:mechanismOfAction |
IRAK4 protein degrader
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational
|
| gptkbp:target |
gptkb:IRAK4
|
| gptkbp:therapeuticArea |
immunology
|
| gptkbp:bfsParent |
gptkb:Kymera_Therapeutics
|
| gptkbp:bfsLayer |
7
|